HTG Molecular Diagnostics, Inc. ("HTG") is a provider of instruments, reagents, and services for molecular profiling applications. In 2013, the company commercialized its HTG Edge instrument platform and a portfolio of multiplexed profiling panels that leverage HTGâs proprietary nuclease protection chemistry. In 2014, the company launched the HTG EdgeSeq system that combines the power of HTG EdgeSeq chemistry and automation with next-generation sequencing (NGS) technology. In 2016, the VERI/O Laboratory Services were introduced to support biopharma clients in research and companion diagnostic development using retrospective samples. Most recently, in 2017, HTG introduced its new DNA mutations chemistry available exclusively in the VERI/O Laboratory Services. Source
No articles found.
Checkpoint Therapeutics, Inc. (âCheckpointâ) is a clinical-stage, immuno-oncol...
Checkpoint Therapeutics, Inc. (âCheckpointâ...
Aurinia is a late clinical stage biopharmaceutical company focused on developing a...
Aurinia is a late clinical stage biopharmaceuti...
Chimerix is a development-stage biopharmaceutical company dedicated to acceleratin...
Chimerix is a development-stage biopharmaceutic...
Armed with cutting-edge technology and MIT science, experienced business and medic...
Armed with cutting-edge technology and MIT scie...
Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company developing novel p...
Evogene (NASDAQ, TASE: EVGN) is a leading biote...
Check-Cap is a clinical-stage medical diagnostics company developing C-ScanÂŽ, the...
Check-Cap is a clinical-stage medical diagnosti...
Harvard Bioscience is a global developer, manufacturer and marketer of a broad ran...
Harvard Bioscience is a global developer, manuf...
Join the National Investor Network and get the latest information with your interests in mind.